Survival Data for Patients Younger Than 60 With Primary Myleofibrosis--Mayo Clinic Proceedings

Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most mature data currently available of patients with primary myelofibrosis younger than 60 years. These 176 patients were followed up for a median of 8 years or until death. Improvement in survival was noted in those with high- and moderate-risk disease but not in those with low-risk disease. These findings suggest a salutary effect of recent treatment approaches, but prospective controlled trials are needed to confirm such an effect.

Category:

Science & Technology

Tags:

• Mayo Clinic
• Mayo Clinic Proceedings
• Tefferi
• Primary Myelofibrosis

[74westy]

The standard treatment has been to watch and wait. Blood transfusions may be the reason for increased survival. Dr. Tefferi, what treatments have you prescribed that may account for the increased survival?

[mayoclinic]

@74westy Good question but difficult to answer accurately. I suspect that most of the improvement comes with better supportive care and not necessarily from better drugs. Dr. Tefferi

[MyKarenLynn]

This is fantastic news for those of us with myelofibrosis!!